Study of three drugs for advanced CML and Ph+ AML
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of three drugs (decitabine, lisaftoclax, and olverembatinib) for people with advanced chronic myeloid leukemia or Philadelphia chromosome-positive acute myeloid leukemia who have not responded to or could not tolerate previous treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You have a specific type of leukemia: advanced chronic myeloid leukemia or Philadelphia chromosome-positive acute myeloid leukemia.
- You have tried at least one prior targeted therapy (BCR::ABL1 inhibitor) and it did not work or you could not tolerate it.
- Your overall health status allows for daily activities with some help (ECOG performance status 0-3).
- Your liver, kidneys, heart, and pancreas are working well enough based on blood tests.
- You cannot have had a previous allergic reaction to any of the study drugs.
- You cannot have had acute pancreatitis in the last year or have chronic pancreatitis.
- You cannot have serious, uncontrolled heart problems or a recent heart attack or stroke.
- You must be able to take pills by mouth.
- If you are able to become pregnant, you must use effective birth control during the study and for 6 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a combination of three drugs (FLAG-Ida, venetoclax, and asciminib) to see if it is effective and safe for people with certain types of leukemia (CML in blast phase or Ph+ AML) that are new or have come back after treatment. The goal is to see if this combination can control the disease and possibly lead to remission.
This trial combines three drugs to treat certain types of leukemia or a related blood condition. It may be an option for people who cannot have standard intensive chemo, or for those whose disease has come back.
This trial tests a combination of three medicines—azacitidine, venetoclax, and gilteritinib—in people with specific gene changes (FLT3 mutations) in leukemia and related bone marrow diseases that have come back or are hard to treat. The goal is to see if this drug combination can control the disease and improve outcomes.
This trial tests a combination of three drugs (olverembatinib, venetoclax, and azacitidine) for people with a fast-growing form of chronic myeloid leukemia (CML) called blast phase. The goal is to see if this treatment can help control the leukemia when it has moved to a more aggressive stage.
This trial tests a new combination of three drugs (a third-generation TKI, azacitidine, and a Bcl-2 inhibitor) for people with chronic myeloid leukemia that has progressed to a more advanced phase (myeloid blast phase). The goal is to see if this combination is safe and effective.
This trial tests two medicines together: olverembatinib (a pill) and blinatumomab (given by infusion). It is for people who are newly diagnosed with Ph+ ALL and have not had chemotherapy yet. The goal is to see if this combination works well and is safe.
Hear when a new Advanced Chronic Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.